Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma

Clinical Cancer Research

Volumn 2, Issue 1, 1996, Pages 107-118

  Houghton, Janet A ^a   Cheshire, Pamela J ^a   Hallman II, James D ^a   Lutz, Lois ^a   Luo, Xialolong ^a   Li, Yulan ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; FLUOROURACIL; IRINOTECAN;

ANIMAL EXPERIMENT; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; MICE; MICE, INBRED CBA; NEOPLASM TRANSPLANTATION; RHABDOMYOSARCOMA; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030034610     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-1-carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47: 5944-5947, 1987.
2. Matsuzaki, T., Yokokura, T., Mutai, M., and Tsuruo, T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol., 21: 308-312, 1988.
3. Bissery, M. C., Mathieu-Boué, A., and Lavelle, F. Preclinical evaluation of CPT-11, a camptothecin derivative (Abstract). Proc. Am. Assoc. Cancer Res., 33: 402, 1991.
4. Bissery, M. C., Mathieu-Boué, A., and Lavelle, F. Experimental activity of CPT-11 in vitro and in vivo (Abstract). Ann. Oncol., 3 (Suppl. 1): 93, 1992.
5. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., and Matsumoto, K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28: 192-198, 1991.
6. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boué, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase 1 inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53: 2823-2829, 1993.
7. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II., Lutz, L., Friedman, H S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
8. Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H., and Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21: 71-74, 1988.
9. Taguchi, T., Wakui, A., and Hasegawa, K. Phase I clinical study of CPT-11. Gan To Kagaku Ryoho, 17: 115-120, 1990.
10. Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K., and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10: 1225-1229, 1992.
11. Fujita, A., Takabatake, H., Tagaki, S., and Sekine, K. Pilot study of irinotecan in refractory small cell lung cancer. Gan To Kagaku Ryoho, 22: 889-893, 1995.
12. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H , Ichimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Yokomaku, S., and Ota, K. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8: 1907-1912, 1990.
13. Fukuoka, M., Niitanim, H., Suzuki, A., Motomiya, M., Hasegawa, K , Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., and Taguchi, T. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol , 10: 16-20, 1992.
14. Fukuoka, M., and Masuda, N. Clinical studies of irinotecan and in combination with cisplatin. Cancer Chemother. Pharmacol., 34 (Suppl): S105-S111, 1994.
15. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., Ogawa, N., and the CPT-11 Gastrointestinal Cancer Study Group. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993.
16. Nishimura, G., Satou, T., Yoshimitsu, Y., Kurosaka, Y., Fujimura, T., Sugiyama, K., Yonemura, Y., et al. Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer. Gan To Kagaku Ryoho, 22: 93-97, 1995.
17. Rougier, P., Culine, S., Bugat, R., Brunet P., Douillard, I. Y., Ychou, M., Marty, M., Bonneterre, J., Ganem, G., Seitz, J. F., Negrier, S., Namer, M., Conroy, T., Burki, F., Shearer, J. P., Mathieue-Boué, A., Mahjoubi, M., and Herait, P. Multicentric phase II study of first line CPT-11 (irinotecan) in advanced colorectal cancer (CRC): preliminary results (Abstract). Proc. Am. Soc. Clin. Oncol., 13: A585, 1994.
18. Rothenberg, M. L., Eckardt, J. R., Burris, H. A., Nelson, J., Kuhn, J. G., Chen, S. F., Hilsenbeck, S. G., Clark, G. M., Fields, S. M., Rodriguez, G. I., Weiss, G. R., Smith, L. S , Thurman, A. M., Eckhardt, S. G., Rinaldi, D. A., Perez, E., and Von Hoff, D D. Irinotecan (CPT-11) as second-line therapy for patients with 5-FU-refractory colorectal cancer (Abstract). Proc. Am. Soc. Clin. Oncol., 13: 200, 1994.
19. Pitot, H. C., Wender, D., O'Connell, M. J., Wieand, H. S., and Mailliard, J. A. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study (Abstract). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 13: 197, 1994.
20. Burris, H. A., Rothenberg, M. L., Kuhn, J. G., and Von Hoff, D. D. Clinical trials with the topoisomerase I inhibitors. Semin. Oncol., 19: 663-669, 1993.
21. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucoronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
22. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Takifuji, N., Nakagawa, K. Tamanoi, M., Nitta, T., Hirashima, T., Negoro, S., and Takada, M. Phase I and pharmacologic study of irinotecan in combination with eisplatin for advanced lung cancer. Br. J. Cancer, 68: 777-782, 1993.
23. Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Nakagawa, K., Hirashima, T., Tamanoi, M., Nitta, T., Yana, T., Negoro, S., Takifuji, N., and Takada, M. Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small cell lung cancer. J. Clin. Oncol., 12: 90-96, 1994.
24. Shinkai, T., Arioka, H , Kunikane, H., Eguchi, K., Sasaki, Y., Tamura, T., Ohe, Y., Oshita, F. Nishio, M., Karato, A., Okamoto, H., Nakashima, H , Ohmatsu, H., Shiraishi, J., Nomura, N , and Saijo, N. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose vindesine in advanced non-small cell lung cancer. Cancer Res., 54: 2636-2642, 1994.
25. Shimada, Y., Sasaki, Y., Sugano, K., Shirao, K., Kondo, H., Yokota, T., Saito, D., Tamura, T., Ohe, Y. Shinaki, T., Eguchi, K., Saijo, N., Shintani, S., Nitta, T., Yana, H., and Takada, M. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer (Abstract). Proc. Am Assoc. Clin. Oncol., 12: 196, 1993.
26. Negoro, S., Fukuoka, M., Masuda, N., Kusunoki, Y., Matsui, K., Kudoh, S., Takifuji, N., Nakagawa, K., Hirashima, T., Tamanoi, M., et al. Phase I study of irinotecan (CPT-11) and etoposide (E) with G-CSF in advanced lung cancer (Abstract). Proc Am. Assoc. Clin. Oncol. Annu. Meet., 12: 133, 1993.
27. Masuda, N., Fukuoka, M., Kudoh, S., Matsui, K., Kusunoki, Y., Takada, M., Nakagawa, K., Hiroshima, T., Tsukuda, H., Yana, T., Yoshikawa, A., Kuba, A., Matsura, E., Nitta, T., Takifuji, N., Terakawa, K., and Negoro, S. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J. Clin. Oncol., 12: 1833-1841, 1994.
28. Lonn, U., and Lonn, S. Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. Cancer Res., 44: 3414-3418, 1984.
29. Dusenbury, C. E., Davis, M A., Lawrence, T. S , and Maybaum, J. Induction of megabase DNA fragments by 5-fluorodeoxyuridine in human colorectal (HT29) cells. Mol. Pharmacol., 39: 285-289, 1991.
30. Kufe, D W., Scott, P., Fram, R., and Major, P. Biologic effect of 5-fluoro-2′-deoxyuridine incorporation in L1210 deoxyribonucleic acid. Biochem. Pharmacol., 32: 1337-1340, 1983.
31. Schuetz, J. D., Wallace, H. J., and Diasio, R. B. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res., 44: 1358-1363, 1984.
32. Goulian, M., Bliele, B., and Tseng, B. Y. The effect of methotrexate on levels of dUTP in animal cells. J. Biol. Chem., 255: 10630-10637, 1980.
33. Jackson, R. C., Jackman, A. L., and Calvert, A. H. Biochemical effects of a quinazoline inhibitor of thymidylate synthase, CB3717, on human lymphoblastoid cells. Biochem. Pharmacol., 32: 3783-3790, 1983.
34. Wang, J. C. Recent studies of topoisomerases. Biochim. Biophys. Acta., 909: 1-9, 1987.
35. Mattern, M. R , Zwelling, L. A., Kerrigan, D. J., and Kohn, K. W. Reconstitution of higher order DNA structure following X-irradiation. Biochem. Biophys. Res. Commun., 112: 1077-1084, 1983.
36. Mattern, M. R., Hofmann, G. A., McCabe, F. L., and Johnson, R. K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res., 51: 5813-5816, 1991.
37. Boothman, D. A., Wang, M., Schea, R. A., Burrows, H. L., Strickfaden, S., and Owens, J. K. Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys., 24: 939-948, 1992.
38. Boothman, D. A., Fukanaga, N., and Wang, M. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res., 54: 4618-4626, 1994.
39. D'Arpa, P., Beardmore, C., and Lui, L. F. Involvement of nucleic acid synthesis in killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
40. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 51: 1129-1136, 1991.
41. Bertrand, R., O'Connor, P. M., Kerrigan, D., and Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer 28A: 743-748, 1992.
42. Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., Lieber, M., Cossman, J., Gottesman, M. M., and Pastan, I. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst., 81: 116-124, 1989.
43. Houghton, P J., Houghton, J. A., Myers, L., Cheshire, P. J., Howbert, J. J., and Grindey, G. B. Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma. Cancer. Chemother Pharmacol., 25: 84-88, 1989.
44. Houghton, J. A., Houghton, P. J., and Webber, B. L. Growth and characterization of childhood rhabdomyosarcomas as xenografts. J. Natl. Cancer. Inst , 68, 437-443, 1982.
45. Houghton, J. A., Cook, R. L., Lutz, P J., and Houghton, P. J. Childhood rhabdomyosarcoma xenografts: response to DNA interacting agents and agents used in current clinical therapy. Eur. J. Cancer. & Clin. Oncol., 20: 955-960, 1984.
46. Houghton, J. A., and Taylor, D. M. Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br. J. Cancer, 37: 213-219, 1978.
47. Houghton, J. A., and Taylor, D. M. Maintenance of biological and biochemical characteristics of human colorectal tumors during serial passage in immune-deprived mice. Br. J. Cancer. 37: 199-212, 1978.
48. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors Cancer Chemother. Pharmacol., 31: 229-239, 1992.
49. Houghton, J. A., Cheshire, P. J., Morton, C L, and Stewart, C. F. Potentiation of 5-fluorouracil-leucovorin activity by α2α-interferon in colon adenocarcinoma xenografts. Clin. Cancer Res., 1: 33-40, 1995.
50. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
51. Peto, R., Pike, M. C., Amitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part 2. Analysis and examples. Br. J. Cancer., 35: 1-39, 1977.
52. Westfall, P. H., and Young, S. S. P-value adjustments for multiple tests in multivariate binomial models. J. Am. Stat. Assoc., 84: 780-786, 1989.
53. Wang, J. C. DNA topoisomerases Annu. Rev. Biochem., 54, 665-697, 1985.
54. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., and Hertzberg, R. P. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1990.
55. Del-Bino, G. D., Lassota, P., and Darzynkiewicz, Z. The S-phase cytotoxicity of comptothecin. Exp. Cell Res., 193: 27-35, 1991.
56. Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T., and Okada, K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer, 50: 760-766, 1992.
57. Houghton, P. J., Shapiro, D. N., and Houghton, J. A. Rhabdomyosarcoma: from the laboratory to the clinic. Pediatr. Clin. North Am., 38: 349-364, 1991.
58. Hakim, F. T., Zujewski, J. A., Tolcher, A., Cepeda, R., Weiss, R., O'Shaughnessy, J., Cowan, K., and Gress, R. Topotecan treatment increases the percentage of CD34+ bone marrow cells in cycle (Abstract). Proc. Am. Assoc. Cancer Res., 36: 452, 1995.
59. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.